ribociclib
novartis
['breast', 'biomarker', 'ribociclib']
 interesting to find, after #asco23, what #breastcancer #patients make of 3% absolute reduction in relapse risk with #adjuvant #ribociclib. can we pick winners based on #biomarkers?
Cancer specialist searching the world for better therapy